Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Novel Approaches in Cancer Study

Different Faces of Fas Signaling in Cancer Cells

Submission: September 10, 2019; Published: September 16, 2019

DOI: 10.31031/NACS.2019.03.000559

ISSN:2637-773X
Volume3 Issue2

Abstract

Fas signaling pathway is known to be engaged in elimination of unwanted cells by apoptosis, however, new discoveries presented its alternate face, namely FasR and FasL play pro-cancerous functions facilitating cancer progression, invasion and metastasis. Here, we provide a brief summary of knowledge concerning Fas signaling pathway merits and disadvantages in cancer. Fas molecules were found to be engaged in many pathways induced by different therapeutic compounds, such as aspirin and antibiotics. This suggest that Fas signaling pathway may be employed as adjuvant factor for immunotherapy of variable design. Although, the literature presents some first optimistic results, we must intensify efforts to finally introduce Fasassociated procedures into standard therapeutic options. The Fas signaling is known to exert very variable effects in wide spectrum of cells. The FasR/ FasL (CD95/ CD95L) proteins can be associated with both positive (physiological) and negative (pathological) effects.

Get access to the full text of this article